-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HlEuUNSqbOeKX+FnfldtXay8gspQUbuFOOuy1zlE2nkY8y1b48opU2OQwSt9WHBl v6dr6DTDR9uFyGnvUnIMcA== 0000950127-05-000799.txt : 20051110 0000950127-05-000799.hdr.sgml : 20051110 20051110145608 ACCESSION NUMBER: 0000950127-05-000799 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20051110 DATE AS OF CHANGE: 20051110 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-41938 FILM NUMBER: 051193432 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER RD CITY: TARRYTOWN STATE: NY ZIP: 10591-6707 BUSINESS PHONE: 9143477000 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: NOVARTIS PHARMA AG CENTRAL INDEX KEY: 0001030617 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: LICHTSTRASSE 35 STREET 2: CH-4002 CITY: BASEL STATE: V8 BUSINESS PHONE: 212-830-2474 MAIL ADDRESS: STREET 1: LICHTSTRASSE 35 STREET 2: CH-4002 CITY: BASEL STATE: V8 FORMER COMPANY: FORMER CONFORMED NAME: NOVARTIS INC DATE OF NAME CHANGE: 19970114 SC 13G/A 1 a366_sch13ga.txt REGNERON PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------ SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Regeneron Pharmaceuticals Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common stock - -------------------------------------------------------------------------------- (Title of Class of Securities) 75886F107 - -------------------------------------------------------------------------------- (CUSIP Number) November 8, 2005 - -------------------------------------------------------------------------------- (Date of Event Which Required Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) - --------------------------------- CUSIP No. 75886F107 13G/A Page 2 of 6 Pages - --------------------------------- - -------- ----------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON NOVARTIS PHARMA AG 00-0000000 - -------- ----------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |_| - -------- ----------------------------------------------------------------------- 3 SEC USE ONLY - -------- ----------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION SWITZERLAND - ---------------------------- ------ -------------------------------------------- NUMBER OF SHARES 5 SOLE VOTING POWER 0 ------ -------------------------------------------- BENEFICIALLY OWNED BY SHARED VOTING POWER 6 0 ------ -------------------------------------------- EACH REPORTING SOLE DISPOSITIVE POWER 7 0 ------ -------------------------------------------- PERSON WITH SHARED DISPOSITIVE POWER 8 0 - -------- ----------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 - -------- ----------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |_| - -------- ----------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0 - -------- ----------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON CO - -------- ----------------------------------------------------------------------- - --------------------------------- CUSIP No. 75886F107 13G/A Page 3 of 6 Pages - --------------------------------- Item 1(a). Name of Issuer: Regeneron Pharmaceuticals Inc. Item 1(b). Address of Issuer's Principal Executive Offices: 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Item 2(a). Name of Person Filing: Novartis Pharma AG Item 2(b). Address of Principal Business Office or, if none, Residence: Lichtstrasse 35 CH-4002, Basel Switzerland Item 2(c). Citizenship: Switzerland Item 2(d). Title of Class of Securities: Common stock Item 2(e). CUSIP Number: 75886F107 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) |_| Broker or dealer registered under section 15 of the Act; (b) |_| Bank as defined in section 3(a)(6) of the Act; (c) |_| Insurance company as defined in section 3(a)(19) of the Act; (d) |_| Investment company registered under section 8 of the Investment Company Act of 1940; (e) |_| An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) |_| An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); - --------------------------------- CUSIP No. 75886F107 13G/A Page 3 of 6 Pages - --------------------------------- (g) |_| A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G) (Note: See Item 7); (h) |_| A savings association as defined in section 3(b) of the Federal Deposit Insurance Act; (i) |_| A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; (j) |_| Group, in accordance with Rule 13d-1(b)(1)(ii)(H). If this statement is filed pursuant to Rule 13d-1(c), check this box. |X| Item 4. Ownership. (a) Amount beneficially owned: Zero. (b) Percent of class: Zero. (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: Zero. (ii) shared power to vote or to direct the vote: Zero. (iii) sole power to dispose or to direct the disposition of: Zero. (iv) shared power to dispose or to direct the disposition of: Zero. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]. Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable. Item 8. Identification and Classification of Members of the Group. Not Applicable. - --------------------------------- CUSIP No. 75886F107 13G/A Page 3 of 6 Pages - --------------------------------- Item 9. Notice of Dissolution of Group. Not Applicable. Item 10. Certification. Not applicable. - --------------------------------- CUSIP No. 75886F107 13G/A Page 3 of 6 Pages - --------------------------------- SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 10, 2005 NOVARTIS PHARMA AG By: /s/ Joseph E. Mamie -------------------------------------- Name: Joseph E. Mamie Title: Head of Operational Treasury By: /s/ Christina Ackermann -------------------------------------- Name: Christina Ackermann Title: Head of Legal General Medicine -----END PRIVACY-ENHANCED MESSAGE-----